<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref67">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Huntjens</surname>
    <given-names>D. R.</given-names>
   </name>
   <name>
    <surname>Ouwerkerk-Mahadevan</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Brochot</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Rusch</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Stevens</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Verloes</surname>
    <given-names>R.</given-names>
   </name>
  </person-group> (
  <year>2017</year>). 
  <article-title>Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase I, double-blind, randomized, placebo-controlled first-in-human study in healthy adult subjects</article-title>. 
  <source>Clin. Pharmacokinet.</source>
  <volume>56</volume>, 
  <fpage>1331</fpage>â€“
  <lpage>1342</lpage>. 
  <pub-id pub-id-type="doi">10.1007/s40262-017-0522-8</pub-id>, PMID: 
  <?supplied-pmid 28238203?>
  <pub-id pub-id-type="pmid">28238203</pub-id>
 </mixed-citation>
</ref>
